Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -920.05% | 471.71% | 132.86% | 147.50% | 91.32% |
| Total Depreciation and Amortization | 791.14% | 78.91% | 11.56% | 10.13% | 15.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.51% | -31.65% | 45.10% | -16.78% | -10.90% |
| Change in Net Operating Assets | -8.43% | -74.13% | 127.69% | 1,149.67% | -61.38% |
| Cash from Operations | 11.69% | 31.09% | 365.64% | 733.86% | 73.13% |
| Capital Expenditure | 48.21% | -99.50% | -159.80% | -29.59% | -174.18% |
| Sale of Property, Plant, and Equipment | 80.00% | 133.33% | 100.00% | -33.33% | 0.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.71% | 443.38% | -15.99% | -42.58% | -152.99% |
| Cash from Investing | -13.86% | 175.21% | -52.34% | -39.19% | -218.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.78% | 27.78% | 33.33% | 68.57% | -2.86% |
| Issuance of Common Stock | -14.38% | 35.28% | 512.50% | -15.97% | 7.15% |
| Repurchase of Common Stock | -430.59% | -58.88% | -377.49% | -15.17% | -50.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -114.59% | -63.33% | 1,762.22% | -81.42% | 1,362.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.90% | 224.89% | 301.83% | 113.84% | -95.55% |